Effect and Safety of Diluted Vasopressin Injection for Bleeding Control During Robot-assisted Laparoscopic Myomectomy in Reproductive Women With Uterine Fibroids: A Randomized Controlled Pilot Trial (VALENTINE Trial)

What Was Tested

Researchers studied Vasopressin in this randomized controlled trial publication.

Although there is a growing preference for the use of diluted vasopressin, evidence of its effect and safety is still lacking.

The primary endpoint was to compare estimated blood loss (EBL), and the secondary endpoints were to compare postoperative value and drop ratio of hemoglobin, operation time, transfusion, hospitalization, and complications among the three groups.

Who Took Part

According to the abstract, 39 women were involved.

PubMed tags the participants as women only.

How the Study Was Run

The researchers set it up as a randomized and pilot study.

Random assignment meant chance, not the researchers, decided who got Vasopressin and who got the comparison, which limits bias.

It is described as a pilot, a small early test of whether a larger Vasopressin study would be practical.

What Was Measured

PubMed files the paper under topics including Uterine Myomectomy, Uterine Neoplasms, Robotics, Pilot Projects, Leiomyoma, Vasopressins and Blood Loss, Surgical.

The authors tagged it with the keywords Uterine fibroids, bleeding control, robot-assisted laparoscopic myomectomy and vasopression.

What This Means in Plain Language

The paper is a randomized and pilot study of Vasopressin in 39 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (In vivo (Athens, Greece)), a journal based in Greece.

More context: the Vasopressin compound page, all human trials.